LFST
LifeStance Health Group, Inc.6.88
-0.04-0.58%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.68BP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
8-K
Board director resigns, new appointment
LifeStance Health Group lost board member William Miller, who resigned effective August 19, 2025, without any disagreements. The board swiftly appointed Sarah Personette the next day, granting her 74,766 restricted stock units vesting on time and performance terms. This quick pivot maintains governance continuity amid routine director turnover.
8-K
Q2 revenue up 11%, guidance raised
LifeStance Health Group reported Q2 2025 revenue of $345.3 million, up 11% year-over-year, fueled by 12% higher visit volumes to 2.2 million and an 11% clinician base expansion to 7,708. Adjusted EBITDA climbed 19% to $34.0 million, or 9.8% of revenue, while net loss narrowed to $3.8 million from $23.3 million. The company raised full-year 2025 guidance, targeting Adjusted EBITDA of $140 million to $150 million. Strong cash flow hit $56.6 million, yet reimbursement risks loom large.
10-Q
Q2 FY2025 results
LifeStance Health Group posted solid Q2 FY2025 results, with revenue climbing 11% year-over-year to $345.3M on 12% more patient visits from organic clinician hiring, though total revenue per visit dipped slightly from payor rate shifts. Operating loss narrowed sharply to $3.0M from $15.9M a year ago, while net loss improved to $3.8M ($0.01 per diluted share) versus $23.3M ($0.06), reconciled against 386,733 weighted-average shares with no anti-dilution effects. Cash from operations surged to $61.3M for the half-year, yielding $46.4M free cash flow after $14.9M capex (derived), boosting cash to $188.9M against $272.9M long-term debt under the 2024 Credit Agreement, with $100M revolver fully available and covenants met. Yet reimbursement rate cuts from key payors, like the 14-15% revenue contributors, pose ongoing pressure.
8-K
Annual meeting elects directors
LifeStance Health Group held its annual stockholder meeting on June 3, 2025, electing Teresa DeLuca, Katherine Wood, and Eric Palmer to its board as Class I directors for three-year terms, with strong support for DeLuca and Palmer but notable withholding for Wood. Stockholders ratified PricewaterhouseCoopers as auditors for 2025 and approved executive compensation on an advisory basis. Votes passed decisively. This affirms governance stability amid routine annual proceedings.
8-K
LifeStance appoints new CTO
LifeStance Health Group announced on May 14, 2025, that Chief Digital Officer Pablo Pantaleoni will depart effective July 1, 2025, after driving the company's digital transformation since 2020. Vaughn Paunovich, with over 25 years in healthcare tech including stints at Amwell and UnitedHealth Group, joins as Chief Technology Officer on June 9, 2025, to lead end-to-end technology strategy and enhance patient-clinician experiences. Pantaleoni's separation includes one year's base salary in installments, 12 months of COBRA premiums, and vesting of certain RSUs, subject to release and covenants. This leadership shift bolsters LifeStance's long-term digital roadmap amid scaling mental health services.
IPO
Website
Employees
Sector
Industry
ACHC
Acadia Healthcare Company, Inc.
14.43+0.21
ASTH
Astrana Health Inc.
22.31+0.01
CMPS
COMPASS Pathways Plc - American
6.39-0.20
FCHS
First Choice Healthcare Solutio
0.01+0.00
GRDN
Guardian Pharmacy Services, Inc
30.64+0.20
HCA
HCA Healthcare, Inc.
469.79-7.19
MD
Pediatrix Medical Group, Inc.
22.32-0.37
NUTX
Nutex Health Inc.
171.72-4.06
PNTG
The Pennant Group, Inc.
29.73+0.00
SYRA
Syra Health Corp.
0.07+0.01